South African health officials announced the rollout of Lenacapavir, a long-acting injectable HIV prevention drug administered twice a year [1, 2].
The introduction of this pre-exposure prophylaxis (PrEP) represents a shift in HIV prevention by reducing the frequency of doses required to maintain protection. This low-frequency option aims to increase adherence among high-risk populations who may struggle with daily medication.
Health Minister Dr. Joe Phaahla said, "The availability of Lenacapavir marks a turning point in our fight against HIV" [1]. The national health ministry and the Gauteng provincial health department are coordinating the initial phase of the program.
In Gauteng province, the rollout is currently operating across 133 clinics [3, 4]. A spokesperson for the Gauteng Health Department said the province aims to reach 56,000 high-risk individuals [3]. While the provincial target is specific, other reports indicate the first phase of the national rollout aims to protect over 100,000 people [1].
Clinical trial data on the drug's effectiveness varies by source. Some reports cite a reduction in HIV transmission risk of approximately 99.9% [1], while others state efficacy up to 90% [2]. Despite these results, the program faces significant financial hurdles.
A spokesperson for the U.S. Agency for International Development said, "Cuts to U.S. funding jeopardize the rollout of life-saving interventions like Lenacapavir" [4]. These funding shortfalls threaten the ability of health officials to scale the intervention beyond the initial target groups.
The announcement was made on Friday, June 5 [2]. The program focuses on providing a highly effective alternative to traditional PrEP, which typically requires daily oral pills.
“"The availability of Lenacapavir marks a turning point in our fight against HIV,"”
The transition from daily oral PrEP to a twice-yearly injection removes a significant barrier to HIV prevention: the requirement for perfect daily adherence. However, the tension between medical innovation and geopolitical funding—specifically the reported US aid cuts—suggests that the clinical success of Lenacapavir may be limited by the economic realities of public health infrastructure in South Africa.
